ES2719776T3 - Inhibidores de GSK3 y métodos de uso de los mismos - Google Patents
Inhibidores de GSK3 y métodos de uso de los mismos Download PDFInfo
- Publication number
- ES2719776T3 ES2719776T3 ES13780300T ES13780300T ES2719776T3 ES 2719776 T3 ES2719776 T3 ES 2719776T3 ES 13780300 T ES13780300 T ES 13780300T ES 13780300 T ES13780300 T ES 13780300T ES 2719776 T3 ES2719776 T3 ES 2719776T3
- Authority
- ES
- Spain
- Prior art keywords
- optionally substituted
- compound
- group
- certain embodiments
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC1*C(C)CC1 Chemical compound CC1*C(C)CC1 0.000 description 12
- TYYMYGWTBNTQHZ-UHFFFAOYSA-N CC(C)(C1)CC(Nc2n[nH]c(C(F)(F)F)c2C2c3cc(F)ccc3F)=C2C1=O Chemical compound CC(C)(C1)CC(Nc2n[nH]c(C(F)(F)F)c2C2c3cc(F)ccc3F)=C2C1=O TYYMYGWTBNTQHZ-UHFFFAOYSA-N 0.000 description 1
- DCAIFVKDYWYHDP-UHFFFAOYSA-N CC(C)(C1)CC(Nc2n[nH]c(C)c2C2(C)c3cccc(C(N)=O)c3)=C2C1=O Chemical compound CC(C)(C1)CC(Nc2n[nH]c(C)c2C2(C)c3cccc(C(N)=O)c3)=C2C1=O DCAIFVKDYWYHDP-UHFFFAOYSA-N 0.000 description 1
- GQFUYSHWMLTFPZ-UHFFFAOYSA-N CC(C)(C1)CC(Nc2n[nH]c(C)c2C2c3ccc(C)cc3)=C2C1=O Chemical compound CC(C)(C1)CC(Nc2n[nH]c(C)c2C2c3ccc(C)cc3)=C2C1=O GQFUYSHWMLTFPZ-UHFFFAOYSA-N 0.000 description 1
- YCEJJWWUCHXBOX-UHFFFAOYSA-N CC(C)(C1)CC(Nc2n[nH]c(C)c2C2c3ccn[nH]3)=C2C1=O Chemical compound CC(C)(C1)CC(Nc2n[nH]c(C)c2C2c3ccn[nH]3)=C2C1=O YCEJJWWUCHXBOX-UHFFFAOYSA-N 0.000 description 1
- CNKCQXIXZDUWHE-QFIPXVFZSA-N CC(C)(C1)CC(Nc2n[nH]c(C3CC3)c2[C@@]2(C)c3cc(C(F)(F)F)ccc3)=C2C1=O Chemical compound CC(C)(C1)CC(Nc2n[nH]c(C3CC3)c2[C@@]2(C)c3cc(C(F)(F)F)ccc3)=C2C1=O CNKCQXIXZDUWHE-QFIPXVFZSA-N 0.000 description 1
- IMKJGRXMBFNOGA-UHFFFAOYSA-N CC(C)(C1)CC(Nc2n[nH]cc2C2(C)c3ccccc3)=C2C1=O Chemical compound CC(C)(C1)CC(Nc2n[nH]cc2C2(C)c3ccccc3)=C2C1=O IMKJGRXMBFNOGA-UHFFFAOYSA-N 0.000 description 1
- IMKJGRXMBFNOGA-LJQANCHMSA-N CC(C)(C1)CC(Nc2n[nH]cc2[C@@]2(C)c3ccccc3)=C2C1=O Chemical compound CC(C)(C1)CC(Nc2n[nH]cc2[C@@]2(C)c3ccccc3)=C2C1=O IMKJGRXMBFNOGA-LJQANCHMSA-N 0.000 description 1
- IMKJGRXMBFNOGA-IBGZPJMESA-N CC(C)(C1)CC(Nc2n[nH]cc2[C@]2(C)c3ccccc3)=C2C1=O Chemical compound CC(C)(C1)CC(Nc2n[nH]cc2[C@]2(C)c3ccccc3)=C2C1=O IMKJGRXMBFNOGA-IBGZPJMESA-N 0.000 description 1
- MIVPKTHOMGOFRR-LURJTMIESA-N CC[C@H](C)C[NH+](C)[O-] Chemical compound CC[C@H](C)C[NH+](C)[O-] MIVPKTHOMGOFRR-LURJTMIESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713314P | 2012-10-12 | 2012-10-12 | |
| US201361779394P | 2013-03-13 | 2013-03-13 | |
| PCT/US2013/064716 WO2014059383A1 (en) | 2012-10-12 | 2013-10-11 | Gsk3 inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2719776T3 true ES2719776T3 (es) | 2019-07-16 |
Family
ID=49474737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13780300T Active ES2719776T3 (es) | 2012-10-12 | 2013-10-11 | Inhibidores de GSK3 y métodos de uso de los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9096594B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2909204B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6321662B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2887701C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1122601T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2909204T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2719776T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20190406T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE043853T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT2909204T (cg-RX-API-DMAC7.html) |
| PL (1) | PL2909204T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2909204T (cg-RX-API-DMAC7.html) |
| RS (1) | RS58700B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI2909204T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT201900136T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014059383A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2887701C (en) | 2012-10-12 | 2020-12-15 | The Broad Institute, Inc. | Gsk3 inhibitors and methods of use thereof |
| BR112015023261A2 (pt) | 2013-03-14 | 2017-07-18 | Massachusetts Inst Technology | composições e métodos para expansão e cultura de células-tronco epiteliais |
| EP3166637B1 (en) | 2014-07-10 | 2020-01-29 | The J. David Gladstone Institutes | Compositions and methods for treating dengue virus infection |
| JP6773645B2 (ja) | 2014-09-03 | 2020-10-21 | ザ ブリガム アンド ウィミンズ ホスピタル，インコーポレイテッド | 聴覚障害の治療のための内耳毛細胞を生成するための組成物、システムおよび方法 |
| WO2016061344A1 (en) * | 2014-10-15 | 2016-04-21 | Mirx Pharmaceuticals Llc | Gsk3 inhibitors and their uses |
| WO2017120543A1 (en) | 2016-01-08 | 2017-07-13 | Massachusetts Institute Of Technology | Production of differentiated enteroendocrine cells and insulin producing cells |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| AU2017386417B2 (en) | 2016-12-30 | 2022-07-14 | Frequency Therapeutics, Inc. | 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
| EP3606528B1 (en) | 2017-04-05 | 2023-10-18 | The Broad Institute, Inc. | Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof |
| US11331313B2 (en) | 2017-05-22 | 2022-05-17 | Whitehead Institute For Biomedical Research | KCC2 expression enhancing compounds and uses thereof |
| CN110407769B (zh) * | 2018-04-27 | 2022-11-08 | 复旦大学 | 3,4-二氢-苯并[f][1,4]硫氮杂䓬-5(2H)-酮类化合物及其药物用途 |
| BR112020024931A2 (pt) | 2018-06-05 | 2021-03-09 | Actuate Therapeutics, Inc. | Uso de um inibidor de gsk-3ss |
| US20210299233A1 (en) * | 2018-07-12 | 2021-09-30 | The Children's Medical Center Corporation | Method for treating cancer |
| JP2021533788A (ja) | 2018-08-17 | 2021-12-09 | フリークエンシー セラピューティクス インコーポレイテッド | Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法 |
| US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
| WO2020163812A1 (en) | 2019-02-08 | 2020-08-13 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| US20230014430A1 (en) * | 2019-11-20 | 2023-01-19 | Washington University | Methods and Compositions for Generating Functionally Mature Beta Cells and Uses Thereof |
| WO2023056463A1 (en) * | 2021-09-30 | 2023-04-06 | Trustees Of Tufts College | Glycogen synthase kinase 3 (gsk3) inhibitors for treating ctnnb1 syndrome |
| WO2024081939A2 (en) * | 2022-10-13 | 2024-04-18 | The Broad Institute, Inc. | Glycogen synthase kinase 3 inhibitors and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2024259178A1 (en) | 2023-06-14 | 2024-12-19 | The Broad Institute, Inc. | Glycogen synthase kinase 3 inhibitors and uses thereof |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2722416A1 (de) | 1977-05-18 | 1978-11-30 | Thomae Gmbh Dr K | Neue thiazolo-pyridine |
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| JPH05157164A (ja) | 1991-12-03 | 1993-06-22 | Aisin Aw Co Ltd | 車両用自動変速機のサーボ油圧制御装置 |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| FI954775A7 (fi) | 1993-04-08 | 1995-10-06 | Du Pont Pharmaceuticals Co | Uusia polysyklisiä yhdisteitä ja niiden johdoksia neurotransmittereide n vapautumista edistävinä aineina, jotka ovat käyttökelpoisia kognitii visten häiriöiden hoidossa |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5750528A (en) | 1995-02-01 | 1998-05-12 | The Dupont Merck Pharmaceutical Company | Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| TW526202B (en) | 1998-11-27 | 2003-04-01 | Shionogi & Amp Co | Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity |
| JP2005501800A (ja) * | 2001-02-02 | 2005-01-20 | 三菱ウェルファーマ株式会社 | ジヒドロピラゾロピリジン化合物およびその医薬用途 |
| US6977262B2 (en) | 2001-02-02 | 2005-12-20 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds and pharmaceutical use thereof |
| DE10121217A1 (de) | 2001-04-30 | 2002-10-31 | Merck Patent Gmbh | 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden |
| WO2002100399A1 (en) | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| KR20060070486A (ko) * | 2003-06-13 | 2006-06-23 | 젠타리스 게엠베하 | 포스파티딜이노시톨 3-키나제의 억제 활성을 갖는 화합물및 이의 사용 방법 |
| PL1746097T3 (pl) * | 2005-07-20 | 2010-06-30 | Aventis Pharma Sa | Skondensowane heterocykle 1,4-dihydropirydynowe, sposób ich wytwarzania, zastosowanie i zawierające je kompozycje |
| WO2008016123A1 (en) | 2006-08-03 | 2008-02-07 | Takeda Pharmaceutical Company Limited | GSK-3β INHIBITOR |
| US8778986B1 (en) | 2007-01-25 | 2014-07-15 | University Of South Florida | Treatment of glycogen synthase kinase-based disease |
| US20090181986A1 (en) | 2007-07-05 | 2009-07-16 | Matthew Abelman | Substituted heterocyclic compounds |
| WO2010098888A1 (en) | 2009-02-27 | 2010-09-02 | Massachusetts Institute Of Technology | Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders |
| FR2945535B1 (fr) * | 2009-05-18 | 2011-06-10 | Sanofi Aventis | Compose anticancereux et composition pharmaceutique le contenant |
| DE102011106990B3 (de) | 2011-07-08 | 2013-01-03 | Technische Universität Darmstadt | Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen |
| TW201406758A (zh) | 2012-06-28 | 2014-02-16 | Daiichi Sankyo Co Ltd | 三環性化合物 |
| US20160375006A1 (en) | 2012-10-12 | 2016-12-29 | The Broad Institute, Inc. | Uses of paralog-selective inhibitors of gsk3 kinases |
| CA2887701C (en) | 2012-10-12 | 2020-12-15 | The Broad Institute, Inc. | Gsk3 inhibitors and methods of use thereof |
| JP2014139870A (ja) * | 2013-01-21 | 2014-07-31 | Hitachi Consumer Electronics Co Ltd | 照明装置およびこれを用いた映像表示装置 |
| WO2015087996A1 (ja) | 2013-12-13 | 2015-06-18 | 第一三共株式会社 | イミダゾピリジン誘導体 |
| KR101602559B1 (ko) | 2014-04-29 | 2016-03-10 | 경북대학교 산학협력단 | 2,5,6,7-사중치환 티아졸로[4,5-b]피리딘 유도체 및 이의 용도 |
| US10437707B2 (en) * | 2015-03-19 | 2019-10-08 | Teachers Insurance And Annuity Association Of America | Evaluating and presenting software testing project status indicators |
| EP3606528B1 (en) | 2017-04-05 | 2023-10-18 | The Broad Institute, Inc. | Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof |
-
2013
- 2013-10-11 CA CA2887701A patent/CA2887701C/en active Active
- 2013-10-11 WO PCT/US2013/064716 patent/WO2014059383A1/en not_active Ceased
- 2013-10-11 PT PT13780300T patent/PT2909204T/pt unknown
- 2013-10-11 JP JP2015536972A patent/JP6321662B2/ja active Active
- 2013-10-11 SM SM20190136T patent/SMT201900136T1/it unknown
- 2013-10-11 HU HUE13780300A patent/HUE043853T2/hu unknown
- 2013-10-11 US US14/052,661 patent/US9096594B2/en active Active
- 2013-10-11 PL PL13780300T patent/PL2909204T3/pl unknown
- 2013-10-11 ES ES13780300T patent/ES2719776T3/es active Active
- 2013-10-11 RS RS20190292A patent/RS58700B1/sr unknown
- 2013-10-11 LT LTEP13780300.3T patent/LT2909204T/lt unknown
- 2013-10-11 EP EP13780300.3A patent/EP2909204B1/en active Active
- 2013-10-11 SI SI201331368T patent/SI2909204T1/sl unknown
- 2013-10-11 HR HRP20190406TT patent/HRP20190406T1/hr unknown
- 2013-10-11 DK DK13780300.3T patent/DK2909204T3/en active
-
2015
- 2015-07-14 US US14/799,281 patent/US10137122B2/en active Active
-
2018
- 2018-04-05 JP JP2018072831A patent/JP6606691B2/ja active Active
- 2018-11-21 US US16/198,589 patent/US11052080B2/en active Active
-
2019
- 2019-03-05 CY CY20191100268T patent/CY1122601T1/el unknown
-
2021
- 2021-06-10 US US17/344,830 patent/US12419885B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL2909204T3 (pl) | 2019-07-31 |
| JP2015536307A (ja) | 2015-12-21 |
| LT2909204T (lt) | 2019-05-10 |
| CY1122601T1 (el) | 2021-03-12 |
| WO2014059383A1 (en) | 2014-04-17 |
| US10137122B2 (en) | 2018-11-27 |
| RS58700B1 (sr) | 2019-06-28 |
| SMT201900136T1 (it) | 2019-05-10 |
| SI2909204T1 (sl) | 2019-06-28 |
| JP2018150302A (ja) | 2018-09-27 |
| US9096594B2 (en) | 2015-08-04 |
| US20150313890A1 (en) | 2015-11-05 |
| US20220160702A1 (en) | 2022-05-26 |
| US20140107141A1 (en) | 2014-04-17 |
| US11052080B2 (en) | 2021-07-06 |
| PT2909204T (pt) | 2019-03-21 |
| US12419885B2 (en) | 2025-09-23 |
| DK2909204T3 (en) | 2019-04-01 |
| CA2887701C (en) | 2020-12-15 |
| JP6606691B2 (ja) | 2019-11-20 |
| HRP20190406T1 (hr) | 2019-05-31 |
| US20200061050A9 (en) | 2020-02-27 |
| EP2909204A1 (en) | 2015-08-26 |
| EP2909204B1 (en) | 2018-12-05 |
| US20190175584A1 (en) | 2019-06-13 |
| HUE043853T2 (hu) | 2019-09-30 |
| JP6321662B2 (ja) | 2018-05-09 |
| CA2887701A1 (en) | 2014-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2719776T3 (es) | Inhibidores de GSK3 y métodos de uso de los mismos | |
| JP7200282B2 (ja) | サイクリン依存性キナーゼの阻害剤 | |
| CN104350055B (zh) | 作为mnk1和mnk2调节剂的二环杂芳基衍生物及其用途 | |
| CN110958882B (zh) | 作为糖原合酶激酶3(gsk3)抑制剂的三环化合物及其用途 | |
| US20160375006A1 (en) | Uses of paralog-selective inhibitors of gsk3 kinases | |
| KR20160111520A (ko) | 디히드로프테리디논 유도체 및 그의 용도 | |
| KR20190075043A (ko) | 비시클릭 우레아 키나제 억제제 및 그의 용도 | |
| JP2018522867A (ja) | 縮合二環式ピリミジン誘導体およびこれらの使用 | |
| HK1256417A1 (zh) | 氰基噻吩並三唑並二氮雜環庚三烯及其用途 | |
| HK40013946A (en) | Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof | |
| HK40013946B (en) | Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof | |
| WO2014036595A1 (en) | Compounds and methods for treating diseases or conditions associated with the central nervous system and/or neurite outgrowth | |
| HK1237593A1 (en) | Dihydropteridinone derivatives and uses thereof |